Study of drug combinations for lymphoma that has spread to the brain
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests whether adding either methotrexate or thiotepa to the standard R-CHOP regimen plus orelabrutinib can better treat diffuse large B-cell lymphoma (DLBCL) that has spread to the central nervous system (brain or spinal cord). The goal is to see if these combinations improve outcomes for patients with this type of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 80 years old.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
- The lymphoma has spread to your brain or spinal cord, as confirmed by symptoms, imaging, or lab tests.
- Your vital organs (like bone marrow, liver, kidneys) are functioning well enough to safely receive the study drugs.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and you agree to use birth control if applicable.
- You have recovered from any side effects of previous treatments, except for hair loss.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of chemotherapy and a targeted drug (zanubrutinib) for people with a type of lymphoma (DLBCL) that has spread to the brain or spinal fluid. The goal is to see if this treatment can better control the disease and improve outcomes.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a new targeted drug (pirtobrutinib) combined with standard chemotherapy and immunotherapy for people with a fast-growing lymphoma that has spread to the brain or spinal cord. The goal is to see if this combination can more effectively treat the lymphoma in these hard-to-reach areas.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Hear when a new CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.